Photo of Andrew H. Lichtman,  MD, PhD

Andrew H. Lichtman, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6532
Fax: (617) 732-5795


alichtman@rics.bwh.harvard.edu

Andrew H. Lichtman, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Pathology, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our laboratory investigates the regulation of T cell mediated immune responses. One project focuses on functional interactions between endothelium and T lymphocytes. We study how vascular endothelial cells support selective recruitment and activation of different T cell subsets. Recent work focuses on the differential expression among T cell subsets of functional ligands for endothelial selectins. In vivo approaches include studies of peripheral recruitment of adoptively transferred mouse T cells in normal mice and adoptively transferred human T cells in human skin grafted onto SCID mice. A second major project in the laboratory concerns cytokine gene regulation in helper T cell subsets: The aim of this project is to determine the molecular basis for differential cytokine gene expression in helper T cell subsets. Studies are focused on the transcriptional regulation of IL-4 and interferon-gamma gene expression during and after mouse T cell subset differentation.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest 2021. PubMed
  • Mysore V, Cullere X, Mears J, Rosetti F, Okubo K, Liew PX, Zhang F, Madera-Salcedo I, Rosenbauer F, Stone RM, Aster JC, von Andrian UH, Lichtman AH, Raychaudhuri S, Mayadas TN. FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. Nat Commun 2021; 12:4791. PubMed
  • Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019; 40:511-523. PubMed
  • Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc Res 2019; 115:869-877. PubMed
  • Lichtman AH. A role for T helper cells in anti-CTLA-4 therapy. Sci Immunol 2017. PubMed
  • Azcutia V, Bassil R, Herter JM, Engelbertsen D, Newton G, Autio A, Mayadas T, Lichtman AH, Khoury SJ, Parkos CA, Elyaman W, Luscinskas FW. Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47-/- mice from EAE. J Leukoc Biol 2017; 101:493-505. PubMed
  • Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375:1749-1755. PubMed
  • Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, Bair S, Newton G, Lichtman AH, Kung AL, Yang T, Wang H, Luscinskas FW, Croce KJ, Bradner JE, Plutzky J. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 2014. PubMed
  • Griffin GK, Lichtman AH. Two sides to every proinflammatory coin: new insights into the role of dendritic cells in the regulation of T-cell driven autoimmune myocarditis. Circulation 2013. PubMed
  • Shah SM, Drage MG, Lichtman AH, Haddad RI. Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread. J Clin Oncol 2012; 30:e321-3. PubMed
  • Griffin GK, Newton G, Tarrio ML, Bu DX, Maganto-Garcia E, Azcutia V, Alcaide P, Grabie N, Luscinskas FW, Croce KJ, Lichtman AH. IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol 2012; 188:6287-99. PubMed
  • Bu DX, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 2011. PubMed
  • Bu DX, Tarrio M, Grabie N, Zhang Y, Yamazaki H, Stavrakis G, Maganto-Garcia E, Pepper-Cunningham Z, Jarolim P, Aikawa M, García-Cardeña G, Lichtman AH. Statin-induced kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 2010; 120:1961-70. PubMed
  • Packard RR,Lichtman AH,Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 2009; 31:5-22. PubMed
  • Gotsman I,Sharpe AH,Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res 2008; 103:1220-31. PubMed
  • Packard RR,Maganto-Garcia E,Gotsman I,Tabas I,Libby P,Lichtman AH. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 2008; 103:965-73. PubMed
  • Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007; 117:2974-82. PubMed
  • Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res 2007; 101:248-57. PubMed
  • Taqueti VR, Grabie N, Colvin R, Pang H, Jarolim P, Luster AD, Glimcher LH, Lichtman AH. T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J Immunol 2006; 177:5890-901. PubMed
Hide